Listar por autor "Touloupidis, S."
Mostrando ítems 1-3 de 3
-
Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC)
Panteliadou, M.; Touloupidis, S.; Giatromanolaki, A.; Pistevou, K.; Kyrgias, G.; Tsoutsou, P.; Kalaitzis, C.; Koukourakis, M. I. (2011)Cisplatin-based radio-chemotherapy is an effective alternative to cystectomy. The position of cisplatin has been challenged by novel drugs, while altered radiotherapy fractionation is also tested against conventional ... -
Mismatch repair hMSH2, hMLH1, hMSH6 and hPMS2 mRNA expression profiles in precancerous and cancerous urothelium
Vageli, D. P.; Giannopoulos, S.; Doukas, S. G.; Kalaitzis, C.; Giannakopoulos, S.; Giatromanolaki, A.; Koukoulis, G. K.; Touloupidis, S. (2013)Changes in the expression of the mismatch repair (MMR) genes hMSH2, hMLH1, hMSH6 and hPMS2 reflect dysfunction of the DNA repair system that may allow the malignant transformation of tissue cells. The aim of the present ... -
Treatment of Low-risk Prostate Cancer with Radical Hypofractionated Accelerated Radiotherapy with Cytoprotection (HypoARC): An Interim Analysis of Toxicity and Efficacy
Koukourakis, M. I.; Kyrgias, G.; Papadopoulou, A.; Panteliadou, M.; Giatromanolaki, A.; Sivridis, E.; Mavropoulou, S.; Kalogeris, K.; Nassos, P.; Milioudis, N.; Touloupidis, S. (2011)Aim: Radiobiological analysis of clinical data suggests that prostate cancer has a low alpha/beta ratio, implying that large radiotherapy fractions may better control the disease. Acceleration of radiotherapy may be also ...